<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027625</url>
  </required_header>
  <id_info>
    <org_study_id>NABTC-0102</org_study_id>
    <secondary_id>CDR0000069049</secondary_id>
    <nct_id>NCT00027625</nct_id>
  </id_info>
  <brief_title>Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma</brief_title>
  <official_title>A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer&#xD;
      cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Combining gefitinib with chemotherapy&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining gefitinib with temozolomide in&#xD;
      treating patients who have malignant primary glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of gefitinib when given in combination with&#xD;
           temozolomide in patients with malignant primary glioma.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of gefitinib. Patients are stratified&#xD;
      according to use of concurrent enzyme-inducing anti-epileptic drugs (yes vs no).&#xD;
&#xD;
      Patients receive oral gefitinib once daily on days 1-35 and oral temozolomide once daily on&#xD;
      days 8-12 for the first course only. For the second and subsequent courses, patients receive&#xD;
      oral gefitinib once daily on days 1-28 and oral temozolomide once daily on days 1-5. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 1 year and then every 3-6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-42 patients will be accrued for this study within 1-14&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2002</start_date>
  <completion_date type="Actual">November 1, 2005</completion_date>
  <primary_completion_date type="Actual">March 17, 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant primary glioma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Anaplastic mixed oligoastrocytoma&#xD;
&#xD;
               -  Malignant astrocytoma not otherwise specified&#xD;
&#xD;
          -  Stable or progressive disease&#xD;
&#xD;
               -  Progressive disease after interstitial brachytherapy or stereotactic radiosurgery&#xD;
                  must be confirmed by positron emission tomography or thallium scan, magnetic&#xD;
                  resonance spectroscopy, or surgical biopsy&#xD;
&#xD;
          -  Prior treatment for no more than 3 prior relapses allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 120,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT less than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other concurrent significant medical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No significant gastrointestinal risk factors (e.g., active ulcerative colitis) within&#xD;
             the past 6 months&#xD;
&#xD;
          -  No other malignancy within the past 3 years except non-melanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 1 week since prior interferon&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) during the first course of study therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior vincristine&#xD;
&#xD;
          -  At least 3 weeks since prior procarbazine&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas&#xD;
&#xD;
          -  Prior or concurrent temozolomide allowed if there is no evidence of progression while&#xD;
             receiving therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 1 week since prior tamoxifen&#xD;
&#xD;
          -  Must be on a stable dose of corticosteroids for at least 5 days&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior surgical resection&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior gefitinib&#xD;
&#xD;
          -  At least 1 week since prior non-cytotoxic agents except radiosensitizers&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  At least 3 years since prior therapy for other malignancy&#xD;
&#xD;
          -  Concurrent therapeutic agents allowed at stable dosage&#xD;
&#xD;
          -  Concurrent enzyme-inducing anti-epileptic drugs allowed if continued during study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Prados, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UCSF Medical Center at Parnassus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-6220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol. 2008 May;61(6):1059-67. Epub 2007 Aug 11.</citation>
    <PMID>17694310</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

